Benitec Biopharma (BNTC) Non Operating Investment Income (2019 - 2023)
Benitec Biopharma (BNTC) reported Non Operating Investment Income of -$1000.0 for Q4 2023, up 66.67% on a YoY basis from -$600.0 in Q4 2022, and down 200.0% sequentially from $1000.0 in Q2 2023.
Benitec Biopharma (BNTC) Non Operating Investment Income (2019 - 2023) Analysis & Trends
Benitec Biopharma (BNTC) has 5 years of Non Operating Investment Income data on file, last reported at -$1000.0 in Q4 2023.
- For the quarter ending Q4 2023, Non Operating Investment Income rose 66.67% year-over-year to -$1000.0; the trailing twelve-month figure through Dec 2024 stood at -$1000.0 (up 75.0% YoY), and the FY2024 full-year result was -$1000.0, up 66.67% from the prior year.
- Non Operating Investment Income slipped to -$1000.0 in Q4 2023, from $1000.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $19000.0 in Q2 2021 to a low of -$23000.0 in Q4 2021.
- A 5-year average of $71.43 and a median of -$1000.0 in 2019 frame the typical range for Non Operating Investment Income.
- Across the five-year window, Non Operating Investment Income slumped 2200.0% in 2021 and surged 200.0% in 2023, its largest moves.
- Tracing BNTC's Non Operating Investment Income over 5 years: stood at -$1000.0 in 2019, then changed by 0.0% to -$1000.0 in 2020, then tumbled by 2200.0% to -$23000.0 in 2021, then soared by 86.96% to -$3000.0 in 2022, then soared by 66.67% to -$1000.0 in 2023.
- Business Quant data shows BNTC's Non Operating Investment Income at -$1000.0 in Q4 2023, $1000.0 in Q2 2023, and -$4000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | - |
| 10 | Benitec Biopharma | 531.19 Mn | 342.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Mar 31, 2023 | -4,000.00 |
| Mar 31, 2023 | -4,000.00 |
| Dec 31, 2022 | -3,000.00 |
| Dec 31, 2022 | -3,000.00 |
| Sep 30, 2022 | 3,000.00 |
| Sep 30, 2022 | 3,000.00 |
| Jun 30, 2022 | -1,000.00 |
| Jun 30, 2022 | -1,000.00 |
| Mar 31, 2022 | -5,000.00 |
| Mar 31, 2022 | -5,000.00 |
| Dec 31, 2021 | -23,000.00 |
| Dec 31, 2021 | -23,000.00 |
| Sep 30, 2021 | 18,000.00 |
| Sep 30, 2021 | 18,000.00 |
| Jun 30, 2021 | 19,000.00 |
| Jun 30, 2021 | 19,000.00 |